<DOC>
	<DOCNO>NCT02054299</DOCNO>
	<brief_summary>The purpose study determine effect organic cation transporter OCT1 polymorphisms pharmacokinetics several drug order explain efficacy adverse effect .</brief_summary>
	<brief_title>Open Label Pharmacokinetic-Pharmacogenetic Study Polymorphisms Organic Cation Transporter OCT1</brief_title>
	<detailed_description />
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Thiamine</mesh_term>
	<criteria>1 . Written inform consent obtain prior study entry include informed consent molecular genetic analysis concern candidate gene relevant pharmacokinetics pharmacodynamics study medication . 2 . Both gender ( male female ) , far feasible , 3 OCT1 genotype group , equal proportion male female include . 3 . Healthy adult age ≥18 &lt; 50 year 4 . Body weight less 48 kg body mass index ( BMI ) less 17 kg/m² great 32 kg/m² . 5 . Willingness meet study instruction cooperate study personal 6 . No clinically relevant pathological finding investigation screen visit . Minor deviation laboratory value normal range may accept , judge investigator clinical relevance 7 . Systolic blood pressure ≤ 140 mmHg ≥ 100 mmHg , diastolic blood pressure ≤ 90 mmHg ≥ 60 mmHg heart rate ≤ 90 bpm ≥ 50 bpm screen visit 8 . Female subject include express willingness become pregnant entire study period practice abstinence reliable method contraception specify respective protocol section . 1 . Unwillingness inability give inform consent 2 . Involvement plan conduct study ( applies staff directly employ study site / department ) 3 . Participation clinical study use investigational nonregistered drug vaccine study period within 30 day precede first dose study drug . 4 . Blood , plasma thrombocyte donation last 15 day prior application test drug . 5 . Any planned surgical treatment last 14 day prior 14 day application test drug . 6 . Known pregnancy lactation period 7 . Any relevant pathological finding investigation screen visit include significant abnormality result medicalscreeninglaboratoryanalysis , especially liver kidney relate parameter unless judge medically irrelevant . 8 . QTcF &gt; 450 m screen ECG 9 . Systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg , diastolic blood pressure &gt; 90 mmHg &lt; 60 mmHg heart rate &gt; 90 bpm &lt; 50 bpm predose treatment period 4 ( Amitriptyline ) 10 . Any disease affect liver kidney impairment liver kidneyfunction 11 . Any cardiovascular disease 12 . Moderate severe hypertension require medication therapy 13 . Bronchogenic asthma require constant drug treatment ( stag 2 4 asthma ) 14 . Diabetes mellitus , hyperthyroidism , hypothyroidism 15 . Glaucoma 16 . Symptomatic prostatic hyperplasia 17 . Any medical constellation increase risk bleeding , include chronic treatment NSAID COX2 inhibitor 18 . History alcohol and/or drug abuse and/or abusive use medicament and/or positive drug screen 19 . History psychiatric neurologic disorder . If doubt screen visit whether person suffer depression exclude study examine psychiatrist clarification inclusion . 20 . Any major gastrointestinal disease gastrointestinal disorder expect significantly interfere pharmacokinetics study drug 21 . Gastrointestinal surgery may interfere pharmacokinetics study drug ( except appendectomy herniotomy ) 22 . Taking medication within 7 day trial follow exception : Oral contraceptive drug use document exclusion criterion . Other medication might allow single case basis consider necessary subject 's safety wellbeing interaction study medication judge irrelevant . 23 . Any finding could compromise safety participant quality studyresults 24 . Any known hypersensitivity allergic reaction test drug 25 . History severe hypersensitivity reaction anaphylaxis 26 . Any clinically significant disease judge investigator 27 . Body temperature &gt; 37.5°C prior drug application 28 . Known infection HIV , Hepatitis B ( HBsAg ) Hepatitis C ( laboratory diagnostics concern disease perform within present study ) 29 . Inability unwillingness avoid intake alcohol 48 h prior 72 hour Investigational Medicinal Product ( IMP ) application application 30 . Pregnancy ( positive pregnancy test perform prior drug administration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>